Could a common antiviral drug help fight deadly brain cancer?
NCT ID NCT04116411
First seen Jan 05, 2026 · Last updated May 13, 2026 · Updated 21 times
Summary
This study tests whether adding the antiviral drug valganciclovir to standard treatment can help people with glioblastoma, an aggressive brain cancer. The drug targets a common virus (CMV) found in most of these tumors, which may make the cancer more aggressive. About 220 adults with newly diagnosed glioblastoma will receive either valganciclovir or a placebo alongside their usual therapy to see if it improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oslo University Hospital
Oslo, Norway
-
SE01 Karolinska University Hospital
Solna, Stockholm County, SE17164, Sweden
-
Stavanger University Hospital
Stavanger, Norway
Conditions
Explore the condition pages connected to this study.